Orthomyxoviridae Infections clinical trials
The registry lists 95 studies for Orthomyxoviridae Infections across more than 10 countries. 1 are recruiting or about to start. 16 of them are mainly about Orthomyxoviridae Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-15. Counting its 2 narrower conditions too, such as Influenza, Human: 2,407 studies, 185 open.
Get an email when these change. Save the Orthomyxoviridae Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Sanofi Pasteur, a Sanofi Company (20) · Medicago (9) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Novartis Vaccines (4) · AVIR Green Hills Biotechnology AG (3) · Sanofi (3) · Hualan Biological Engineering, Inc. (2) · University of Minnesota (2)
What is being tested here
Drugs under test in Orthomyxoviridae Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Sep 2027Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza · National Institute of Allergy and Infectious Diseases (NIAID)
Who these studies take
No Orthomyxoviridae Infections study is recruiting now.
Across all 95 studies, recruiting or not: 51% stop at 75 or younger and 48% at 65; 36% take children; 2% are for women only and 3% for men only; 68% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 95. Browse all 95 → or search them.
- Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 InfluenzaEnrolling by invitationNCT07215871Phase 11 country
- Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress SyndromeCompletedNCT036416901 country
- A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or UnprimedCompletedNCT05422326Phase 21 country
- Study of SAB-176 in Healthy Adult ParticipantsCompletedNCT04850898Phase 21 country
- Respiratory Virus Hospitalization Study (FLU 003 Plus)CompletedNCT0105618512 countries
- H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 21 country
- A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol PlusCompletedNCT06385821Phase 31 country
- Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ACompletedNCT03315104Phase 24 countries
- Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge StrainCompletedNCT05572450Not applicable1 country
- Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsCompletedNCT03301051Phase 37 countries
- Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy AdultsCompletedNCT03321968Phase 31 country
- Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/mlTerminatedNCT04810949Not applicable1 country
- ECMO for COVID-19 vs Influenza A H1N1 Associated ARDSCompletedNCT050809331 country
- Comparison of COVID-19 and H1N1 Influenza PneumoniaCompletedNCT04933994
- Tomographic Findings in COVID-19 and Influenza H1N1Status unknownNCT044993781 country
- Tomographic Findings in COVID-19 and InfluenzaStatus unknownNCT044973111 country
- Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy AdultsCompletedNCT02768805Phase 22 countries
- Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.CompletedNCT01991561Phase 21 country
- Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsCompletedNCT01991587Phase 1/21 country
- Panblok H7 Vaccine Adjuvanted With AS03 or MF59CompletedNCT03283319Phase 21 country
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in AdultsCompletedNCT02233816Phase 21 country
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly PopulationCompletedNCT02236052Phase 21 country
- Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly AdultsCompletedNCT02831751Phase 22 countries
- A Pilot Study for Collection of Anti-Influenza A Immune PlasmaCompletedNCT009844511 country
- Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy AdultsCompletedNCT037436881 country
- Centralized Reminder Recall - Flu RCT2CompletedNCT03294473Not applicable1 country
- Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)CompletedNCT033922071 country
- A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With InfluenzaCompletedNCT01231620Phase 328 countries
- Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected AdultsCompletedNCT01155037Phase 21 country
- Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United KingdomCompletedNCT009968531 country
- Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating InfluenzaCompletedNCT01052480Phase 21 country
- The Immune Response to Influenza Vaccinations in Elderly IndividualsCompletedNCT03266237Phase 41 country
- Respiratory Virus Outpatient Study (FLU 002 Plus)CompletedNCT0105635415 countries
- Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedNCT00996307Phase 2/32 countries
- STIP: Statin Trial for Influenza PatientsTerminatedNCT00970606Not applicable1 country
- Study of the Safety and Immunogenicity of H1N1 VaccineCompletedNCT01177202Phase 11 country
- Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the ElderlyCompletedNCT00391053Phase 31 country
- Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in AdultsCompletedNCT00772109Phase 32 countries
- Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® VaccineCompletedNCT00561002Phase 41 country
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)CompletedNCT00972816Phase 2/32 countries
- Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®CompletedNCT00755274Phase 41 country
- Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV AloneCompletedNCT01498718Phase 11 country
- Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIVCompletedNCT01946594Phase 41 country
- Infectivity, Replication & Immunogenicity of Live nH1N1 VaccineCompletedNCT01023776Phase 41 country
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly AdultsCompletedNCT00973349Phase 2/32 countries
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)CompletedNCT00973700Phase 31 country
- Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.CompletedNCT02022163Phase 11 country
- Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza VaccinesCompletedNCT00776438Phase 21 country
- Rapid Diagnostic Test for InfluenzaCompletedNCT010898161 country
- DNA-based Influenza Vaccine in the ElderlyCompletedNCT01587131Phase 11 country